News

November 13, 2017

Alexo Therapeutics to Present ALX148 Preclinical Data at the 59th American Society of Hematology Annual Meeting (ASH)  Read more   Download

November 10, 2017

Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma  Read more   Download

October 5, 2017

Alexo Therapeutics to Present ALX148 Clinical Data at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC)  Read more   Download

April 10, 2017

Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma  Read more   Download

July 25, 2016

BioCentury Emerging Company Profile of Alexo Therapeutics  Read article

Upcoming Events

59th American Society of Hematology Annual Meeting (ASH)

December 9, 2017, 10:15 am ET – Atlanta, Georgia

Oral presentation (#112): ALX148 Is a High Affinity SIRPα Fusion Protein that Blocks CD47, Enhances the Activity of Anti-Cancer Antibodies and Checkpoint Inhibitors, and Has a Favorable Safety Profile in Preclinical Models